Stefano Aquaro

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. pmc Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages
    Matteo Surdo
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    PLoS ONE 8:e68076. 2013
  2. pmc The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
    Francesc Cunyat
    IrsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias, Universitat Autonoma de Barcelona, Catalonia, Spain
    Retrovirology 9:15. 2012
  3. pmc Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage
    Salvatore Dimonte
    University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Retrovirology 8:33. 2011
  4. pmc Peroxynitrite decomposition catalyst prevents apoptotic cell death in a human astrocytoma cell line incubated with supernatants of HIV-infected macrophages
    Carolina Muscoli
    Faculty of Pharmacy, University of Catanzaro Magna Graecia, Roccelletta di Borgia, Catanzaro, Italy
    BMC Neurosci 3:13. 2002
  5. pmc Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs
    Claudia Alteri
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata Rome, Italy
    BMC Infect Dis 9:111. 2009
  6. ncbi request reprint Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy
    C F Perno
    Istituto di Ricovero e Cura a Carattere Scientifico L Spallanzani, and Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
    J Infect Dis 184:983-91. 2001
  7. doi request reprint Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs
    Carlo Federico Perno
    Department of Experimental Medicine and Biochimical Science, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 80:565-76. 2008
  8. doi request reprint The discovery and development of HIV therapy: the new challenges
    Carlo Federico Perno
    Dipartimento di Medicina Sperimentale e Scienze Biochimiche, Universita degli Studi Tor Vergata, Rome, Italy
    Ann Ist Super Sanita 47:41-3. 2011
  9. ncbi request reprint Antiviral profile of HIV inhibitors in macrophages: implications for therapy
    C F Perno
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier, 1 00133 Roma, Italy
    Curr Top Med Chem 4:1009-15. 2004
  10. ncbi request reprint Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed
    Carlo Federico Perno
    Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, University of Rome Tor Vergata, Italy
    J Infect Dis 189:1983-7. 2004

Detail Information

Publications95

  1. pmc Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages
    Matteo Surdo
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    PLoS ONE 8:e68076. 2013
    ....
  2. pmc The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
    Francesc Cunyat
    IrsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias, Universitat Autonoma de Barcelona, Catalonia, Spain
    Retrovirology 9:15. 2012
    ....
  3. pmc Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage
    Salvatore Dimonte
    University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Retrovirology 8:33. 2011
    ..The binomial correlation phi coefficient was used to assess covariation among gp120V3 and gp41 mutations; subsequently the average linkage hierarchical agglomerative clustering was performed...
  4. pmc Peroxynitrite decomposition catalyst prevents apoptotic cell death in a human astrocytoma cell line incubated with supernatants of HIV-infected macrophages
    Carolina Muscoli
    Faculty of Pharmacy, University of Catanzaro Magna Graecia, Roccelletta di Borgia, Catanzaro, Italy
    BMC Neurosci 3:13. 2002
    ..Here we investigated the role of peroxynitrite in apoptosis occurring in astroglial cells incubated with supernatants of HIV-infected human primary macrophages (M/M)...
  5. pmc Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs
    Claudia Alteri
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata Rome, Italy
    BMC Infect Dis 9:111. 2009
    ..This study is aimed to assess the prevalence and the patterns of the mutations recently associated with transmitted drug resistance in the reverse transcriptase (RT) and in protease (PR) of HIV-1...
  6. ncbi request reprint Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy
    C F Perno
    Istituto di Ricovero e Cura a Carattere Scientifico L Spallanzani, and Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
    J Infect Dis 184:983-91. 2001
    ..20; 95% confidence interval, 1.30-3.75; P= .004). If confirmed in independent studies, this result may justify the increased use of HIV genotyping in drug-naive patients requiring antiretroviral therapy...
  7. doi request reprint Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs
    Carlo Federico Perno
    Department of Experimental Medicine and Biochimical Science, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 80:565-76. 2008
    ....
  8. doi request reprint The discovery and development of HIV therapy: the new challenges
    Carlo Federico Perno
    Dipartimento di Medicina Sperimentale e Scienze Biochimiche, Universita degli Studi Tor Vergata, Rome, Italy
    Ann Ist Super Sanita 47:41-3. 2011
    ..The revision of the criteria of evidence-based medicine, and their adaptation to the new tools available, may allow a better contribution to the definition of the best therapy for each single patient...
  9. ncbi request reprint Antiviral profile of HIV inhibitors in macrophages: implications for therapy
    C F Perno
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier, 1 00133 Roma, Italy
    Curr Top Med Chem 4:1009-15. 2004
    ....
  10. ncbi request reprint Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed
    Carlo Federico Perno
    Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, University of Rome Tor Vergata, Italy
    J Infect Dis 189:1983-7. 2004
    ..5 [95% confidence interval, 1.89-95.6]; P=.009) and, possibly, of 10I/V. This suggests a potential role for the presence of 36I at baseline in predicting the appearance of 90M at virological failure...
  11. ncbi request reprint Therapeutic strategies towards HIV-1 infection in macrophages
    Carlo Federico Perno
    National Institute for Infectious Diseases L Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Antiviral Res 71:293-300. 2006
    ..Moreover, testing new and promising antiviral compounds in such cells may provide crucial hints about their efficacy in patients infected by HIV...
  12. ncbi request reprint Virologic correlates of adherence to antiretroviral medications and therapeutic failure
    Carlo Federico Perno
    INMI L Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 31:S118-22. 2002
    ....
  13. ncbi request reprint Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation
    Carlo Federico Perno
    IRCCS L Spallanzani Hospital, Via Portuense 292, 00149 Rome, Italy
    AIDS 16:619-24. 2002
    ..To assess the prevalence of mutations in the reverse-transcriptase (RT) and protease (PR) region in a cohort of chronically-infected HIV-positive patients requiring highly active antiretroviral therapy (HAART)...
  14. ncbi request reprint Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome, Rome, Italy
    J Leukoc Biol 80:1103-10. 2006
    ..A better understanding of the activity of the anti-HIV drugs in M/M may represent a key element for the design of effective anti-HIV chemotherapy...
  15. ncbi request reprint Profound anti-HIV-1 activity of DAPTA in monocytes/macrophages and inhibition of CCR5-mediated apoptosis in neuronal cells
    Michela Pollicita
    Department of Experimental Medicine and Biochemical Science, University of Rome Tor Vergata, Rome, Italy
    Antivir Chem Chemother 18:285-95. 2007
    ....
  16. ncbi request reprint Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome
    J Antimicrob Chemother 55:872-8. 2005
    ....
  17. doi request reprint Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes
    Fernanda Scopelliti
    University of Rome Tor Vergata, Rome, Italy
    Antiviral Res 92:255-61. 2011
    ..4, 0.9, 11.5 nM in macrophages, in PBMCs and T cells, respectively; for L870,810, the EC(50) was 1.5, 14.3, and 10.6 nM, respectively; for IN5 the EC(50) was 0.5, 13.7, and 5.7 nM, respectively...
  18. pmc Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Antimicrob Agents Chemother 53:2816-23. 2009
    ..This highlights the multiple roles of ENF (and perhaps other entry inhibitors) in modulating the correct interplay between the different HIV-1 genes and proteins during the HIV-1 life cycle...
  19. ncbi request reprint The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage?
    Mauro Zaccarelli
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Curr HIV Res 2:283-92. 2004
    ..Phenotypic hypersusceptibility has been demonstrated for all three drug classes. Particularly, NNRTI hypersusceptibility, associated with NRTI mutations, is analyzed and discussed...
  20. ncbi request reprint Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, 00149 Rome, Italy
    AIDS Res Hum Retroviruses 24:787-96. 2008
    ..In contrast, early changes in PVL levels were not. Virologic failure was associated with detection of emergent DRMs. Virologic rebound in patients on salvage-HAART should be addressed aggressively...
  21. ncbi request reprint Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure
    M Zaccarelli
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149, Rome, Italy
    Infection 37:203-9. 2009
    ..To assess the role of viral suppression on clinical progression following a genotypic resistance test (GRT), we have examined a database on patients failing to respond to combined antiretroviral therapy (cART)...
  22. ncbi request reprint Potent antiviral activity of amprenavir in primary macrophages infected by human immunodeficiency virus
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellie 1, Rome 00133, Italy
    Antiviral Res 61:133-7. 2004
    ..These findings suggest that amprenavir (at relatively high concentrations) has a clinically relevant antiviral effect in persistently infected reservoirs of HIV...
  23. ncbi request reprint Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 68:479-88. 2002
    ..In conclusion, the long-term dynamics and the high cumulative virus production that characterize HIV-1 infection of macrophages underscore the peculiar role of these cells as a persistently infected reservoir of HIV...
  24. ncbi request reprint gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure
    Roberta D'Arrigo
    Spallanzani Institute for Infectious Diseases, Rome, Italy
    AIDS Res Hum Retroviruses 23:1296-302. 2007
    ....
  25. ncbi request reprint Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome, Tor Vergata, Rome, Italy
    J Antimicrob Chemother 58:714-22. 2006
    ..To investigate gp41 variability and correlation with viro-immunological parameters in 54 HIV-1-infected patients receiving enfuvirtide added as single active drug to a failing regimen...
  26. ncbi request reprint Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Antivir Ther 11:553-60. 2006
    ..Drug-class-wide resistance (DCWR) to antiretrovirals substantially reduces treatment options...
  27. doi request reprint The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Hepatol 50:461-70. 2009
    ..To investigate the different clusters of mutations associated with lamivudine resistance in HBV genotypes D and A...
  28. pmc Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria
    Maria Mercedes Santoro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    AIDS Res Hum Retroviruses 24:1133-8. 2008
    ..Furthermore, surveillance of PR and RT sequences is also convenient to monitor the introduction of nonsubtype B HIV-1 strains in Bulgaria...
  29. ncbi request reprint Clinical implications of HIV-1 drug resistance in the neurological compartment
    Andrea Antinori
    National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
    Scand J Infect Dis Suppl 106:41-4. 2003
    ....
  30. ncbi request reprint Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    J Infect Dis 189:1688-95. 2004
    ..We evaluated the effect of RT mutations associated with hypersusceptibility to NNRTIs on the response to efavirenz-based therapy...
  31. ncbi request reprint Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation
    Mauro Zaccarelli
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 8:51-6. 2003
    ..M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment...
  32. ncbi request reprint The V118I mutation as a marker of advanced HIV infection and disease progression
    Mauro Zaccarelli
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 12:163-8. 2007
    ..We focused on the V1181 mutation in order to evaluate factors associated with its detection and its relationship with HIV progression...
  33. ncbi request reprint Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 9:743-52. 2004
    ..This work was presented in part at the First European Workshop on HIV Drug Resistance. Luxembourg, 4-6 March 2003 (Abstract 44); and at the 9th European Conference on CIinical AIDS Therapy. Warsaw, 25-28 October 2003 (Abstract F6/7)...
  34. doi request reprint HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Antiviral Res 90:42-53. 2011
    ....
  35. ncbi request reprint Phylogenetic analysis of the surface proteins of influenza A (H5N1) viruses isolated in Asian and African populations
    Muhammed Babakir-Mina
    Laboratory of Molecular Virology, University Hospital Tor Vergata, Rome, Italy
    New Microbiol 32:397-403. 2009
    ..So, although all H5N1 viruses were derived from ancestors circulating in south-east Asia more than ten years ago, since 2003 they have evolved into geographically distinct groups within each country...
  36. ncbi request reprint Interpretation systems for genotypic drug resistance of HIV-1
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Scand J Infect Dis Suppl 106:29-34. 2003
    ..Importantly, only 8 systems were intended for clinical use and 5 of these had at least partially undergone clinical validation...
  37. ncbi request reprint HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment
    Carlo Federico Perno
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Scand J Infect Dis Suppl 106:37-40. 2003
    ....
  38. ncbi request reprint Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study
    Maria Mercedes Santoro
    University of Tor Vergata, Rome, Italy
    AIDS Patient Care STDS 22:7-16. 2008
    ..The antiviral efficacy of atazanavir is greater when boosted with low-dose ritonavir...
  39. ncbi request reprint HIV-1-associated dementia during HAART therapy
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    Recent Pat CNS Drug Discov 3:23-33. 2008
    ..In this review, we outline the current state of knowledge regarding the pathophysiology of CNS injury in HIV-1 infection and will focus on the effects of HAART on CNS...
  40. ncbi request reprint Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy
    Mauro Zaccarelli
    Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Rome, Italy
    Clin Infect Dis 38:433-7. 2004
    ..A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients...
  41. ncbi request reprint Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 9:583-93. 2004
    ....
  42. pmc Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Antimicrob Agents Chemother 54:3938-48. 2010
    ....
  43. pmc Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice
    Enrico Garaci
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy
    Proc Natl Acad Sci U S A 100:8927-32. 2003
    ..This may open new perspectives of experimental approaches aimed at selectively eliminating persistently infected macrophages from the bodies of HIV-infected patients...
  44. doi request reprint Identification of the novel KI Polyomavirus in paranasal and lung tissues
    Muhammed Babakir-Mina
    Laboratory of Molecular Virology, University Hospital Tor Vergata, Rome, Italy
    J Med Virol 81:558-61. 2009
    ..In vitro studies are needed to investigate the transforming potential of KIV strains...
  45. ncbi request reprint Does residual virus replication during successful HAART lead to HIV-1 genetic evolution?
    Stefano Aquaro
    Department of Pharmaco Biology, University of Carabria, Reude, Rome, Italy
    J HIV Ther 11:84-8. 2006
  46. ncbi request reprint Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier, 1, 00133, Rome, Italy
    Antiviral Res 55:209-25. 2002
    ..Testing new and promising antiviral compounds in such cells may provide crucial hints about their efficacy in patients infected by HIV...
  47. doi request reprint Dynamics of NRTI resistance mutations during therapy interruption
    Maria Trignetti
    Experimental Medicine Department, University of Rome Tor Vergata, 00133, Rome, Italy
    AIDS Res Hum Retroviruses 25:57-64. 2009
    ..Overall, it seems that the loss of NRTI drug resistance mutations during TI is not an ordered process, and in the majority of patients occurs without specific interaction among mutations...
  48. pmc Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 80:7186-98. 2006
    ....
  49. ncbi request reprint HIV Type 1 replication in cerebrospinal fluid of patients with AIDS-related non-Hodgkin's lymphoma receiving chemotherapy and antiretroviral therapy
    Maria Letizia Giancola
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Via Portuense 292, 00149, Rome, Italy
    AIDS Res Hum Retroviruses 19:1091-5. 2003
    ....
  50. ncbi request reprint Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1)
    Ornella Franzese
    Department of Neuroscience, Section of Pharmacology and Medical Oncology, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 79:639-46. 2007
    ..Telomerase was found to be downregulated in both nuclear and cytoplasmic compartments, together with an impairment of human telomerase reverse transcriptase (hTERT) expression and of the cell machinery involved in hTERT phosporylation...
  51. ncbi request reprint Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: role of cells of monocyte-macrophage lineage
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    J Neurovirol 11:58-66. 2005
    ..A better understanding of the mechanisms involved in this process may help in a successful therapeutic approach to the neuropathogenesis of HIV infection...
  52. ncbi request reprint Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors
    Andrea Savarino
    Department of Infectious Diseases, Universita Cattolica del Sacro Cuore, Rome, Italy
    J Acquir Immune Defic Syndr 35:223-32. 2004
    ..We tested the effects of chloroquine (CQ) on glycosylation of HIV particles and in combination with protease inhibitors (PIs) on HIV replication and on P-glycoprotein (P-gp)/multidrug resistance protein-1 (MRP1)...
  53. ncbi request reprint Dynamics of viral load rebound in plasma and semen after stopping effective antiretroviral therapy
    Giuseppina Liuzzi
    National Institute for Infectious Diseases L Spallanzani, Rome, Italy
    AIDS 17:1089-92. 2003
    ..The reintroduction of therapy was followed by an overall decrease in HIV-RNA in plasma and semen. One to 2 months after restarting treatment, four out of seven patients showed undetectable HIV-RNA in semen...
  54. ncbi request reprint Understanding HIV compartments and reservoirs
    Valentina Svicher
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    Curr HIV/AIDS Rep 11:186-94. 2014
    ....
  55. doi request reprint Specific VpU codon changes were significantly associated with gp120 V3 tropic signatures in HIV-1 B-subtype
    Salvatore Dimonte
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome 00133, Italy
    Virol Sin 27:360-68. 2012
    ..Some of these pairs of mutations were encoded always by one specific codon. These data indicate the possible VpU mutational patterns contributing to regulation of HIV-1 tropism...
  56. ncbi request reprint Characterization and structural analysis of HIV-1 integrase conservation
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    AIDS Rev 11:17-29. 2009
    ....
  57. doi request reprint Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure
    Valentina Svicher
    Department of Experimental Medicine, University of Tor Vergata Rome, Italy
    J Infect Dis 197:1408-18. 2008
    ..We investigated the correlation of enfuvirtide (ENF)-associated gp41 mutational clusters with viroimmunological parameters, as well as the potential underlying mechanisms...
  58. ncbi request reprint Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Infect Dis 196:1180-90. 2007
    ..A negative association between the polymorphism F214L and type 1 thymidine analogue (TA) mutations (TAMs) has been observed. However, the virological response to TAs according to the detection of F214L has not been evaluated...
  59. pmc Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Antimicrob Agents Chemother 49:2015-25. 2005
    ....
  60. ncbi request reprint Molecular diversity of HIV in Albania
    Massimo Ciccozzi
    Epidemiology Unit, Department of Infectious Diseases, Istituto Superiore di Sanita, Rome, Italy
    J Infect Dis 192:475-9. 2005
    ..In conclusion, non-B subtypes are predominant in Albania, and the prevalence of resistance to antiretroviral drugs is still low...
  61. doi request reprint Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis
    Ilaria Lenci
    Hepatology Unit, Department of Internal Medicine, Tor Vergata University, Via Montpellier 1 00133 Rome, Italy
    Dig Liver Dis 42:578-84. 2010
    ..The risk of HBV reactivation is due to persistence of covalently closed circular (ccc) DNA in hepatocytes. Whether cccDNA persists in livers of long-term transplant survivors who received conventional prophylaxis is unknown...
  62. ncbi request reprint Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions
    Valeria Cento
    Laboratory of Molecular Virology, University Hospital Tor Vergata, Rome, Italy
    J Med Virol 81:1627-34. 2009
    ..7%). The study provides some new data on the genetic diversity of HPV 16 which may help to understand the oncogenic potential of the virus and to improve management of patients...
  63. pmc High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 79:10718-29. 2005
    ..This new knowledge could be of help in the structure-based design of novel resistance-evading drugs...
  64. ncbi request reprint Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients
    Dora Larussa
    Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS, Rome, Italy
    AIDS Res Hum Retroviruses 22:386-92. 2006
    ..These results may have significant implications for the clinical management of the older HIV population...
  65. doi request reprint Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Antimicrob Chemother 65:2305-18. 2010
    ..To define whether the prevalence of mutations associated with integrase inhibitor (INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected individuals (all INI naive)...
  66. ncbi request reprint Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    J Infect Dis 187:1934-43. 2003
    ..GSSs predicted changes in HIV RNA levels better in adherent patients than in nonadherent individuals. Interpretation may be improved, and knowledge should be used uniformly throughout different expert systems...
  67. doi request reprint Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Acquir Immune Defic Syndr 55:336-44. 2010
    ..To investigate genotypic resistance profiles to emtricitabine + tenofovir (FTC + TDF) in-vivo and in-vitro, and compare them with lamivudine + tenofovir (3TC + TDF)...
  68. pmc The contribution of peroxynitrite generation in HIV replication in human primary macrophages
    Stefano Aquaro
    Faculty of Pharmacy, University of Catanzaro Magna Graecia, Roccelletta di Borgia, Catanzaro, Italy
    Retrovirology 4:76. 2007
    ..MnTBAP (Mn(III)tetrakis(4-benzoic acid)porphrin chloride), a synthetic peroxynitrite decomposition catalyst, reduced oxidative stress subsequent to peroxynitrite generation...
  69. pmc Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 81:11507-19. 2007
    ..Mutations beyond those currently known to confer resistance should be considered for a better prediction of clinical response to reverse transcriptase inhibitors and for the development of more efficient new-generation NNRTIs...
  70. ncbi request reprint Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients
    Andrea Antinori
    National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
    AIDS 16:1867-76. 2002
    ..To determine the effectiveness of antiretroviral therapy in controlling cerebrospinal fluid (CSF) HIV-1 replication and to assess factors related to virological response in advanced patients...
  71. ncbi request reprint Assessing the relative efficacy of antiretroviral activity of different drugs on macrophages
    Stefano Aquaro
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    Methods Mol Biol 304:445-53. 2005
    ....
  72. ncbi request reprint Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group
    Valentina Svicher
    University of Rome Tor Vergata, Department of Experimental Medicine, Roma, Italy
    New Microbiol 33:195-206. 2010
    ..The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trofile (ESTA) as reference-assay...
  73. ncbi request reprint Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Tor Vergata University, Rome, Italy
    Curr Opin Infect Dis 16:573-80. 2003
    ....
  74. doi request reprint Identification of Merkel cell polyomavirus in the lower respiratory tract of Italian patients
    Muhammed Babakir-Mina
    Laboratory of Molecular Virology, Foundation University Hospital Tor Vergata, Rome, Italy
    J Med Virol 82:505-9. 2010
    ..This study shows that MCPyV can infect the lower respiratory tract, but further investigations are needed to define its pathogenic role in respiratory diseases. J. Med. Virol. 82:505-509, 2010. (c) 2010 Wiley-Liss, Inc...
  75. ncbi request reprint Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma
    Andrea Antinori
    National Institute for Infectious Diseases, Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
    Clin Infect Dis 41:1787-93. 2005
    ....
  76. doi request reprint Identification of the novel KI polyomavirus in the respiratory tract of an Italian patient
    Muhammed Babakir-Mina
    Laboratory of Molecular Virology, University Hospital Tor Vergata, Viale Oxford, Rome, Italy
    J Med Virol 80:2012-4. 2008
    ..Further investigations are needed to establish an etiological link of KIV with acute respiratory illness...
  77. pmc Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line
    Michela Pollicita
    Department of Experimental Medicine and Biochemical Sciences, University Tor Vergata, Rome, Italy
    BMC Neurosci 10:51. 2009
    ..In the present study we analyzed the potential relations occurring between free radicals formation and telomere length during HIV-1 mediated astroglial death...
  78. ncbi request reprint Influenza virus A (H5N1): a pandemic risk?
    Muhammed Babakir-Mina
    Department of Experimental Medicine and Biochemical Science, University of Roma Tor Vergata, Rome, Italy
    New Microbiol 30:65-78. 2007
    ..Recent outbreaks of highly pathogenic avian influenza A virus (H5N1 subtype) infections in poultry and humans (through direct contact with infected birds) have raised concerns that a new influenza pandemic might occur in the near future...
  79. ncbi request reprint Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy
    Michela Violin
    Institute of Infectious and Tropical Diseases, University of Milan, Italy
    AIDS 18:227-35. 2004
    ..To investigate the impact of 215 HIV-1 revertants on the risk of virological failure of the first thymidine analog-containing highly active antiretroviral therapy (HAART)...
  80. ncbi request reprint The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy
    Bruno Christian Ciancio
    Clinical Department and Laboratory of Antiviral and Antineoplastic Drug Monitoring, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy
    Antivir Ther 8:611-6. 2003
    ..To assess on longitudinal data the impact of number of drug-associated mutations at genotype resistance testing (GRT) and history of previous exposure to antiretrovirals on the virological response to genotype-guided antiretroviral therapy...
  81. ncbi request reprint Novel drug resistance mutations in HIV: recognition and clinical relevance
    Carlo Federico Perno
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Italy
    AIDS Rev 8:179-90. 2006
    ..Such novel mutations should be considered for improved prediction of clinical response to antiretroviral drugs and for assessing the efficacy of next-generation drugs...
  82. ncbi request reprint Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy
    Maria Mercedes Santoro
    Department of Experimental Medicine, Tor Vergata University of Rome, Italy
    New Microbiol 29:89-100. 2006
    ....
  83. ncbi request reprint Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 10:469-77. 2005
    ....
  84. ncbi request reprint Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/microl
    Cristina Mussini
    Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Modena, Italy
    AIDS 16:1551-4. 2002
    ..This decline was unrelated to the CD4 cell count and HIV-RNA values at interruption, but was more profound in patients in whom the M184V mutation had disappeared after lamivudine discontinuation...
  85. ncbi request reprint Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001
    Michela Violin
    J Acquir Immune Defic Syndr 36:761-4. 2004
  86. ncbi request reprint Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation
    Andrea Antinori
    National Institute for Infectious Diseases L Spallanzani IRCCS, Roma, Italy
    Antivir Ther 12:1175-83. 2007
    ..The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined...
  87. ncbi request reprint Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients
    Andrea Antinori
    National Institute for Infectious Diseases L Spallanzani IRCCS, Roma
    Antivir Ther 11:233-43. 2006
    ..To evaluate antiviral efficacy of stavudine/tenofovir (d4T/TDF) backbone combination in late-line antiretroviral therapy, and to assess clinical and virological determinants of treatment success...
  88. ncbi request reprint HIV/AIDS in Africa: treatment as a right and strategies for fair implementation. False assumptions on the basis of a minimalistic approach
    Leonardo Palombi
    AIDS 19:536-7. 2005
  89. ncbi request reprint A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication
    Claudio Casoli
    Department of Clinical Medicine, Nephrology and Health Sciences, University of Parma, Viale Antonio Gramsci 14, 43100 Parma, Italy
    AIDS 20:975-80. 2006
    ....
  90. ncbi request reprint Structured treatment interruption in HIV-infected patients failing on multidrug therapy: is there a future for this strategy?
    Andrea Antinori
    AIDS 19:1691-4. 2005
  91. ncbi request reprint Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 10:375-92. 2005
    ..In addition, the panel formulated a series of position statements that are relevant to the interpretation of current data and can aid the design of future clinical trials...
  92. pmc Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives
    Miguel Stevens
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, and Division of Histopathology, University Hospitals, Leuven, Belgium
    Antimicrob Agents Chemother 51:1407-13. 2007
    ..Since both quinolone derivatives were able to inhibit the reactivation of HIV-1 from this artificial viral reservoir in vivo, we provide encouraging evidence for the use of quinolones in the control of HIV-1 infections...
  93. pmc Evaluation of the Abbott RealTime HBV DNA assay and comparison to the Cobas AmpliPrep/Cobas TaqMan 48 assay in monitoring patients with chronic cases of hepatitis B
    Marco Ciotti
    Laboratory of Clinical Microbiology and Virology, University Hospital Tor Vergata, Viale Oxford, 81 00133 Rome, Italy
    J Clin Microbiol 46:1517-9. 2008
    ..By coupling high sensitivity with a large dynamic range, the Abbott RealTime HBV assay is useful in monitoring the response to antiviral therapy...
  94. ncbi request reprint Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak
    Tulio de Oliveira
    Department of Zoology, University of Oxford, Oxford OX1 3PS, UK
    Nature 444:836-7. 2006
    ....